Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results.
Clinical lymphoma, myeloma & leukemia（2023）
摘要
Dasatinib 50 mg daily is an effective and safe treatment for newly diagnosed CML-CP.
更多查看译文
关键词
chronic myeloid leukemia,frontline therapy,low-dose
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要